Roche's bet on a B7-H3–targeting antibody-drug conjugate (ADC) developed by MediLink is looking solid, judging by late-stage data shared by its China-based partner at the World Conference on Lung Cancer (WCLC) on Sunday.   The Swiss drugmaker in January agreed to splash $570 million in upfront and near-term payments to gain exclusive, ex-China rights to tambotatug pelitecan (Tam-Peli) across a range of solid tumours. According to MediLink, Tam-Peli has already posted positive Phase III results i

The addition of Cullinan Therapeutics and Taiho Pharmaceutical's zipalertinib to chemotherapy extended progression-free survival (PFS) by 6 months when used as a first-line treatment for patients with EGFR exon 20 insertion (ex20ins) mutation-positive non–small-cell lung cancer (NSCLC), according to data presented Monday at the World Conference on Lung Cancer (WCLC)."We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive no

NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chinese as "关爱计划-延伸" of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), with Blau syndrome as the proposed indication. The relevant public notice period ended

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) pl

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently dev

RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Slate Medicines Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Kenneth Koblan, PhD, as Chief Scientific Officer. Dr. Koblan brings more than three decades of experience in drug discovery and development, with deep expertise in ne

Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET 1 Median overall survival reached 34.3 months with the amivantamab-based regimen, the longest reported to date in this patient population 1,2 BEERSE, BELGIUM, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT ® ▼ (amivantam

iStock, efks Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to break through where others have previously failed. Merck and Moderna’s late-stage melanoma win last month marked a triumphant turnaround for the cancer vaccine space after years of middling outcomes. The partners—whose Phase 3 data showed that their mRNA-based cancer vaccine, combined wit

Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governance CAMBRIDGE, Mass.--(BUSINESS WIRE)-- $HIND #CFO --Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry L

SAN FRANCISCO--(BUSINESS WIRE)-- #CMO -- SonoThera , a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the appointment of Adam J. Shaywitz, M.D., Ph.D., as Chief Medical Officer. Dr. Shaywitz brings two decades of biopharmaceutical industry experience spanning early- and late-stage drug development, with particular expertise in genetic medicine, rare diseases, and novel therapeutic platforms. “Adam brings an exceptional co